Publications by authors named "Pascal Poignard"

Claim this Profile
E
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trial.
Clément R Massonnaud, Nathan Peiffer-Smadja, Pascal Poignard, Simon Jamard, François Goehringer

Clin Microbiol Infect· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RBD-depleted SARS-CoV-2 spike generates protective immunity in cynomolgus macaques.
Hélène Letscher, Delphine Guilligay, Gregory Effantin, Axelle Amen, Guidenn Sulbaran, Pascal Poignard

NPJ Vaccines· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-Existing Anti-Vector Immunity to Adenovirus-Inspired VLP Vaccines Shows an Adjuvant-Dependent Antagonism.
Salomé Gallet, Dalil Hannani, Sebastian Dergan-Dylon, Emilie Vassal-Stermann, Isabelle Bally, Pascal Poignard

Vaccines (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variants.
Léa Dépéry, Isabelle Bally, Axelle Amen, Benjamin Némoz, Marlyse Buisson, Pascal Poignard

Microbiol Spectr· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target-agnostic identification of human antibodies to sexual forms reveals cross-stage recognition of glutamate-rich repeats.
Axelle Amen, Randy Yoo, Amanda Fabra-García, Judith Bolscher, William J R Stone, Pascal Poignard

Elife· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial.
Maxime Beaulieu, Alexandre Gaymard, Clément Massonnaud, Nathan Peiffer-Smadja, Maude Bouscambert-Duchamp, Pascal Poignard

J Antimicrob Chemother· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target-agnostic identification of human antibodies to sexual forms reveals cross stage recognition of glutamate-rich repeats.
Axelle Amen, Randy Yoo, Amanda Fabra-García, Judith Bolscher, William J R Stone, Pascal Poignard

bioRxiv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revisiting the interaction between complement lectin pathway protease MASP-2 and SARS-CoV-2 nucleoprotein.
Isabelle Bally, Guillaume Drumont, Véronique Rossi, Serafima Guseva, Maiia Botova, Pascal Poignard

Front Immunol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial.
Maya Hites, Clément R Massonnaud, Eva Larranaga Lapique, Drifa Belhadi, Simon Jamard, Pascal Poignard

J Infect· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies.
Collin Joyce, Sasha Murrell, Ben Murrell, Oluwarotimi Omorodion, Lorena S Ver, Pascal Poignard

PLoS Pathog· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fine Analysis of Lymphocyte Subpopulations in SARS-CoV-2 Infected Patients: Differential Profiling of Patients With Severe Outcome.
Giovanna Clavarino, Corentin Leroy, Olivier Epaulard, Tatiana Raskovalova, Antoine Vilotitch, Pascal Poignard

Front Immunol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform.
Christopher Chevillard, Axelle Amen, Solène Besson, Dalil Hannani, Isabelle Bally, Pascal Poignard

Mol Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence at one year of neutralizing antibodies after SARS-CoV-2 infection: Influence of initial severity and steroid use.
Olivier Epaulard, Marlyse Buisson, Benjamin Nemoz, Marion Le Maréchal, Nicolas Terzi, Pascal Poignard

J Infect· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AKR1B10, One of the Triggers of Cytokine Storm in SARS-CoV2 Severe Acute Respiratory Syndrome.
Clovis Chabert, Anne-Laure Vitte, Domenico Iuso, Florent Chuffart, Candice Trocme, Pascal Poignard

Int J Mol Sci· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection.
Guidenn Sulbaran, Pauline Maisonnasse, Axelle Amen, Gregory Effantin, Delphine Guilligay, Pascal Poignard

Cell Rep Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.
Aurélie Truffot, Julien Andréani, Marion Le Maréchal, Alban Caporossi, Olivier Epaulard, Pascal Poignard

Emerg Infect Dis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality.
Federica Defendi, Corentin Leroy, Olivier Epaulard, Giovanna Clavarino, Antoine Vilotitch, Pascal Poignard

Front Immunol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Clinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study.
Antonin Bal, Karen Brengel-Pesce, Alexandre Gaymard, Grégory Quéromès, Nicolas Guibert, Pascal Poignard

Sci Rep· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study.
Antonin Bal, Karen Brengel-Pesce, Alexandre Gaymard, Grégory Quéromès, Nicolas Guibert, Pascal Poignard

Sci Rep· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An MPER antibody neutralizes HIV-1 using germline features shared among donors.
Lei Zhang, Adriana Irimia, Lingling He, Elise Landais, Kimmo Rantalainen, Pascal Poignard

Nat Commun· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan.
Jeffrey Umotoy, Bernard S Bagaya, Collin Joyce, Torben Schiffner, Sergey Menis, Pascal Poignard

Immunity· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design.
Kimmo Rantalainen, Zachary T Berndsen, Sasha Murrell, Liwei Cao, Oluwarotimi Omorodion, Pascal Poignard

Cell Rep· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.
Elise Landais, Ben Murrell, Bryan Briney, Sasha Murrell, Kimmo Rantalainen, Pascal Poignard

Immunity· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies.
Irene Sanjuan Nandin, Carol Fong, Cecilia Deantonio, Juan A Torreno-Pina, Simone Pecetta, Pascal Poignard

J Exp Med· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies.
Irene Sanjuan Nandin, Carol Fong, Cecilia Deantonio, Juan A Torreno-Pina, Simone Pecetta, Pascal Poignard

J Exp Med· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis